Application of Cristinia parvata in preparation of product for preventing and / or improving obesity and / or glucose and lipid metabolism disorder

Abstract

The invention relates to the field of microorganisms, in particular to application of Cristinia parvata in preparation of products for preventing and / or improving obesity and / or glucose and lipid metabolism disorder. The invention provides Christsenella minuta, and the preservation number of the Christsenella minuta is CGMCC (China General Microbiological Culture Collection Center) No.46901. The invention also provides a preparation method of the Christsenella minuta. The Cristsenella minuta provided by the invention can effectively inhibit the serum uric acid value of an organism, reduce the blood sugar level, improve reproductive injury caused by abnormal metabolism, effectively regulate and control abnormal glucose and lipid metabolism, and can improve symptoms such as obesity and / or hyperuricemia and / or gout diseases.

Description

Technical Field

[0001] This invention relates to the field of microbiology, and more particularly to the use of *Christsenius simulans* in the preparation of products for the prevention and / or improvement of obesity and / or disorders of glucose and lipid metabolism. Background Technology

[0002] Obesity and disorders of glucose and lipid metabolism have become major global public health problems. Their core pathology often manifests as a series of interrelated metabolic abnormalities, including insulin resistance, hyperuricemia, hyperglycemia, and hyperlipidemia. Insulin resistance can lead to compensatory hyperinsulinemia, which directly causes hyperuricemia by promoting renal reabsorption of uric acid. Simultaneously, insulin resistance is also a core mechanism in the development and progression of type 2 diabetes; the coordinated effect of persistent hyperglycemia and hyperuricemia significantly increases the risk of cardiovascular and cerebrovascular diseases. Therefore, lowering blood glucose, reducing serum uric acid levels, and decreasing low-density lipoprotein (LDL) can effectively improve abnormal glucose and lipid metabolism and their related complications. Summary of the Invention

[0003] In view of this, the present invention provides the application of Christensenella minuta in the preparation of products for the prevention and / or improvement of obesity and / or disorders of glucose and lipid metabolism. The Christensenella minuta provided by the present invention can effectively inhibit serum uric acid levels and lower blood glucose levels, improve reproductive damage caused by metabolic abnormalities, and effectively regulate abnormal glucose and lipid metabolism, thereby improving symptoms such as hyperuricemia and gout caused by obesity.

[0004] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0005] This invention provides Christensenella minuta, with accession number CGMCC No. 46901.

[0006] The present invention also provides microbial inoculants, comprising any one of the following and acceptable adjuvants:

[0007] (a) the above-mentioned Christensenella minuta; and / or

[0008] (b) Inactivated strains of the aforementioned Christensenella minuta; and / or

[0009] (c) Metabolites, derivatives, fermentation broth, cultures, exosomes, lysates, or extracts of the aforementioned Christensenella minuta.

[0010] The present invention also provides the use of the above-mentioned Christensenella minuta and / or the above-mentioned microbial agents in the preparation of products for treating and / or preventing obesity, and / or lowering blood sugar.

[0011] The present invention also provides the use of the above-mentioned Christensenella minuta and / or the above-mentioned microbial agents in the preparation of products that improve abnormal glucose metabolism.

[0012] The present invention also provides the application of the above-mentioned Christensenella minuta and / or the above-mentioned microbial agents in the preparation of hypoglycemic products.

[0013] The present invention also provides the use of the above-mentioned Christensenella minuta and / or the above-mentioned microbial agents in the preparation of products that lower low-density lipoprotein.

[0014] The present invention also provides the use of the above-mentioned Christensenella minuta and / or the above-mentioned microbial agents in the preparation of products that improve reproductive damage.

[0015] The present invention also provides the application of the above-mentioned Christensenella minuta and / or the above-mentioned microbial agents in the preparation of products that regulate the intestinal microecology.

[0016] In some embodiments of the present invention, in the above applications, the Christensenella minuta and / or the microbial agent regulate fecal microbiota transplantation.

[0017] The present invention also provides the use of the above-mentioned Christensenella minuta and / or the above-mentioned microbial agents in the preparation of products that improve cognitive function.

[0018] The present invention also provides the application of the above-mentioned Christensenella minuta and / or the above-mentioned microbial agents in the preparation of uric acid-lowering products.

[0019] This invention provides a novel use of *Kristensenium spp.* for the preparation of drugs to prevent, treat, and / or assist in the treatment of obesity and symptoms related to glucose and lipid metabolism disorders. Experimental results show that the *Kristensenium spp.* provided by this invention can lower blood glucose levels and significantly inhibit the increase of serum uric acid and low-density lipoprotein in mice on a high-sugar, high-fat diet. The levels of uric acid and low-density lipoprotein in these mice are comparable to those in the control group on a normal diet, with statistically significant differences (p < 0.05). Furthermore, the results also show that *Kristensenium spp.* has the effect of improving reproductive damage and cognitive impairment in mice on a high-sugar, high-fat diet. Attached Figure Description

[0020] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the description of the embodiments or the prior art will be briefly introduced below.

[0021] Figure 1 Phenotypic changes in the body morphology of mice are shown; where: left is Control; middle is Model; right is high-dose YSG01;

[0022] Figure 2 This study demonstrates the effect of Christensenella minuta intervention on glucose metabolism in the body; different lowercase letters indicate significant differences between groups (p<0.05), while the same lowercase letter indicates no significant differences between groups (p>0.05).

[0023] Figure 3 This study demonstrates the effect of Christensenella minuta intervention on sperm abnormality rate in the body; different lowercase letters indicate significant differences between groups (p<0.05), while the same lowercase letter indicates no significant differences between groups (p>0.05).

[0024] Figure 4 This study investigated the effects of Christensenella minuta intervention on serum biochemical parameters. A represents uric acid (UA); B represents low-density lipoprotein (LDL); and C represents the LDL / HDL ratio. Different lowercase letters indicate significant differences between groups (p<0.05), while the same lowercase letter indicates no significant differences between groups (p>0.05).

[0025] Figure 5This study investigated the effects of Christensenella minuta (YSG01) intervention on behavioral outcomes. Where: A represents the spontaneous alternation rate in the Y maze; B represents the total distance traveled in the open field experiment; C represents the central distance traveled in the open field experiment; and D represents the central time of the open field experiment. Different lowercase letters indicate significant differences between groups (p<0.05), while the same lowercase letter indicates no significant differences between groups (p>0.05).

[0026] Figure 6 An LPS-induced inflammation model of RAW264.7 cells was demonstrated, and the concentration of TNF-α in the supernatant was measured using an ELISA kit. Among them, CM1, CM2, CM3, CM4, CM5, CM6, and CM7 were small cristatus strains isolated from people of different ages. CM2 and CM3 were different small cristatus strains isolated from the same sample; CM4, CM5, and CM6 were different small cristatus strains isolated from the same sample; YSG01 was derived from CM5, which showed the best effect.

[0027] Biological Preservation Instructions

[0028] Biological material: YSG01; Classification and nomenclature: Christensenella minuta; Deposited on November 4, 2025 at the China General Microbiological Culture Collection Center; Address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing; Accession number: CGMCC No. 46901. Detailed Implementation

[0029] This invention discloses the use of *Christsenium micranthum* in the preparation of products for the prevention and / or improvement of obesity and / or disorders of glucose and lipid metabolism.

[0030] It should be understood that the expression “one or more of…” individually includes each of the objects described after the expression, as well as various different combinations of two or more of the described objects, unless otherwise understood from the context and usage. The expression “and / or” combined with three or more described objects should be understood to have the same meaning, unless otherwise understood from the context.

[0031] The terms “including,” “having,” or “containing,” including the use of their grammatical synonyms, should generally be understood as open-ended and non-restrictive, for example, not excluding other unstated elements or steps, unless otherwise specifically stated or understood from the context.

[0032] It should be understood that the order of the steps or the order in which certain actions are performed is not important as long as the invention remains operational. Furthermore, two or more steps or actions can be performed simultaneously.

[0033] The use of any and all instances or exemplary language such as “e.g.” or “including” in this document is merely intended to better illustrate the invention and is not intended to limit the scope of the invention unless the claims are made. No language in this specification should be construed as indicating that any unclaimed element is essential to the practice of the invention.

[0034] Furthermore, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values ​​in the specific embodiments have been presented as precisely as possible. However, any value inevitably contains standard deviations due to individual test methods. Therefore, unless explicitly stated otherwise, it should be understood that all ranges, quantities, values, and percentages used in this disclosure are modified with the word "approximately". Here, "approximately" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a specific value or range.

[0035] Christenellaceae belongs to the phylum Firmicutes and is widely distributed in the intestinal mucosa of humans and animals. Currently discovered species of the genus Christenella include Christenella minuta (C. minuta), Christenella intestinihominis (C. intestinihominis), and Christenella tenuis (C. tenuis). *C. minuta* was initially isolated from the feces of a healthy Japanese donor and was definitively described in 2012 as the first member of the family Christenellaceae in the order Clostridium of the phylum Firmicutes. It is a strictly anaerobic, Gram-negative, short bacillus. Based on 16S rRNA gene sequence analysis, it was named Christensenella minuta DSM 22607 (Morotomi, Masami, Fumiko Nagai, and Yohei Watanabe. "Description of Christensenella minuta gen.nov., sp. nov., isolated from human faeces, which forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam. nov." International journal of systematic and evolutionary microbiology 62.1(2012): 144-149.). In 2014, C. minuta was found to be highly heritable, making it one of the most easily inherited bacteria in humans (Goodrich, Julia K., et al. "Human genetics shape the gut microbiome." Cell159.4 (2014): 789-799.).Subsequently, in different populations and multiple studies, it was found that the relative abundance of Christensenellaceae in the human body was negatively correlated with body mass index (BMI) (Waters, Jillian L., and Ruth E. Ley. "The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health." BMC biology 17.1 (2019): 1-11.).

[0036] Most current studies have found that decreased or even absent C. minuta abundance is potentially related to body weight and inflammatory bowel diseases such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome. However, these results are all based on changes in C. minuta at the 16S or metagenomic sequencing levels under disease states, lacking mechanistic exploration and compelling evidence. A recent related paper reported that dietary supplementation with C. minuta DSM 22607 could inhibit related inflammatory factors and alleviate colitis in both DNBS-induced acute colitis mouse and TNBS-induced acute colitis rat models, but did not delve into further mechanistic exploration (Kropp, Camille, et al. "The Keystone commensal bacterium Christensenellaminuta DSM 22607 displays anti-inflammatory properties both in vitro and invivo." Scientific Reports 11.1 (2021): 1-12.).

[0037] The applicant found that *C. cristatum* significantly inhibited the increase of blood glucose, serum uric acid (UA), and low-density lipoprotein (LDL) levels in mice in a high-sugar, high-fat diet model group, improved reproductive damage and cognitive dysfunction, and showed significant differences compared to the model group. This indicates that *C. cristatum* has significant effects in lowering blood sugar, lowering uric acid, and protecting cardiovascular health, and can effectively regulate abnormal glucose and lipid metabolism, thus improving symptoms such as obesity-induced hyperuricemia and gout.

[0038] This invention provides the use of *Christsenius simulans*, its cellular components, metabolites, and / or secretions in the preparation of products for the prevention, treatment, and / or adjunctive treatment of obesity and symptoms related to glucose and lipid metabolism disorders.

[0039] It is understandable that cellular components include stem cells, the culture medium containing the cells, and various chemical components that make up the cells; metabolites include intermediate and final metabolites in metabolism; and secretions include enzymes, antibodies, and hormones.

[0040] In one embodiment, the Christensenella minora is Christensenella minora YSG01.

[0041] In one embodiment, the drug is *Christsenia minor*, its cellular components, metabolites and / or secretions, and a pharmaceutically acceptable carrier.

[0042] Pharmaceutically acceptable carriers can include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; malt; gelatin; vegetable oils such as peanut oil, corn oil, cocoa butter, and sesame oil; polyols such as glycerol, sorbitol, and mannitol; flavoring agents; tablets; stabilizers; isotonic salt solutions such as physiological saline; and phosphate buffer solutions.

[0043] In one embodiment, the dosage form of the drug is an oral formulation or an injectable formulation.

[0044] In one embodiment, the oral formulation is a tablet, capsule, granule, concentrated pill, or liquid.

[0045] For example, tablets are mainly oral tablets, but also include lozenges, sublingual tablets, oral patches, chewable tablets, dispersible tablets, effervescent tablets, vaginal tablets, immediate-release or sustained-release or controlled-release tablets, and enteric-coated tablets; capsules include hard capsules and soft capsules; granules include soluble granules, suspension granules, effervescent granules, enteric-coated granules, sustained-release granules, and controlled-release granules; concentrated pills include concentrated water pills, concentrated honey pills, and concentrated water-honey pills; liquids include oral solutions, ear solutions, ophthalmic solutions, and external solutions, and this invention does not impose any special limitations on these.

[0046] In one embodiment, the injectable formulation is a liquid injection, an injectable powder, or an injectable tablet.

[0047] For example, liquid injections include solutions (aqueous or non-aqueous) injections, suspension injections, and emulsion injections; powders for injection include sterile powders and lyophilized powders; tablets for injection include molded tablets and machine-compressed tablets made using aseptic methods, and the present invention does not impose any particular limitations on these.

[0048] The standard strain of this invention is DSM22607.

[0049] In Examples 1 and 2 of this invention, the raw materials and reagents used can all be purchased from the market.

[0050] The present invention will be further illustrated below with reference to the embodiments:

[0051] Example 1: Kristensenella pyrenoidosa intervention test

[0052] 1. Experimental materials: Christensenella minuta (YSG01) is a strain isolated and purified from the intestines of healthy newborns by our research group.

[0053] 2. Experimental reagents: blood glucose meter, blood glucose test strips, Shanghai Jianzhen Medical Technology Co., Ltd.

[0054] 3. Laboratory Animals: Male C57BL / 6JNifdc mice, purchased from Guangdong Vital River Laboratory Animal Technology Co., Ltd. (Certificate No.: 44829700048846). They were acclimatized in the Jinan University Laboratory Animal Center with a 12-hour day / night cycle, a temperature of 20-25℃, and a relative humidity of 50±5%, and were allowed free access to food. All experimental procedures were conducted in accordance with the relevant requirements of the Jinan University Laboratory Animal Ethics Committee.

[0055] 4. Experimental Methods

[0056] (1) Grouping of experimental animals and establishment of models

[0057] Male C57BL / 6JNifdc mice were randomly divided into 7 groups using a weight stratification method: Control group, Model group, and experimental group (including: low-dose YSG01 group, high-dose YSG01 group, standard strain, inactivated YSG01, and YSG01 metabolites). The low-dose group consisted of 10... 9 CFU / mL, high dose is 10 10 CFU / mL, the standard strain, inactivated YSG01 and metabolite group were all 10. 9 CFU / mL. YSG01 was inactivated by autoclaving, and the metabolites were obtained by freeze-drying YSG01 culture medium / supernatant. A high-sugar, high-fat diet model was established. Fructose aqueous solution was prepared in pure water and given to the Model and Experimental groups for free drinking. At the same time, the Model and Experimental groups were given a high-fat diet for free intake until the end of the experiment.

[0058] (2) Intervention treatment

[0059] Mice in the experimental groups were subjected to intervention starting four weeks after model establishment and continued until the end of the experiment. The Control and Model groups were administered a corresponding volume (0.2 mL / mice) of PBS buffer via gavage, while the experimental groups were administered a corresponding volume (0.2 mL / mice) of the intervention via gavage.

[0060] (3) Weight

[0061] Mice in all groups were weighed weekly, and their body morphology was photographed and recorded. Obesity was also assessed by calculating the degree of obesity in the mice.

[0062] Obesity level = (actual weight - ideal weight) ÷ ideal weight × 100%

[0063] Obesity within ±10% is considered normal to moderate; obesity exceeding 10% is considered overweight; obesity exceeding 20% ​​to 30% is considered mild obesity; obesity exceeding 30% to 50% is considered moderate obesity; obesity exceeding 50% is considered severe obesity; obesity less than -10% is considered underweight; obesity less than -20% is considered emaciated.

[0064] (4) Blood glucose and OGTT analysis

[0065] After a 6-hour fast, blood was collected from the tail vein of all mice in all groups. Blood glucose levels were measured and recorded using a glucometer and test strips. After a period of water restriction following the 6-hour fast, all mice in all groups were administered a 20% w / v glucose solution via gavage. Blood glucose levels were measured at 0, 15, 30, 60, 90, and 120 minutes after gavage.

[0066] (5) Sperm deformity rate analysis

[0067] Epididymal tissues from all groups of mice were placed in sterile PBS solution preheated at 37°C, the tissues were quickly minced, and then placed in a 37°C water bath for 5 minutes to release the tissues. After thorough mixing, 5 μL of sperm suspension was added to a sperm counting chamber. Sperm were collected dynamically and statically using a sperm analyzer, and the sperm abnormality rate of the mice was recorded and analyzed.

[0068] (6) UA / LDL / HDL analysis

[0069] Before euthanasia at the end of the experiment, mice were fasted for 12 hours but allowed free access to water. Blood was collected from all groups of mice via orbital sampling. After standing at room temperature for 30 minutes, the blood was centrifuged at 3000 rpm / min for 15 minutes at 4°C. The supernatant serum was collected, aliquoted, and stored at -80°C for later use. Subsequently, serum biochemical parameters were measured and analyzed using UA, LDL, and HDL kits (purchased from Nanjing Jiancheng Bioengineering Graduate Co., Ltd.).

[0070] (7) Y-maze / open field analysis

[0071] Sixty minutes before the experiment, all mice in each group were moved to the testing chamber. A camera was fixed directly above the apparatus and the lighting was adjusted to be uniform. The experimental apparatus was cleaned with 75% alcohol and allowed to dissipate the odor. Mice were then released sequentially into the central area of ​​the Y-maze and allowed to explore freely for 6 minutes. The entry and exit sequences were recorded using ANY-maze, and the spontaneous alternation rate of the mice was calculated and analyzed. After the Y-maze experiment, mice rested for ≥30 minutes. Four mice were then placed into an open field test chamber (50cm×50cm×50cm) from the lower right corner facing the center and allowed to explore freely for 10 minutes. The total distance traveled and the time spent in the central area were recorded using KEMaze animal behavior video analysis software.

[0072] (8) LPS-induced inflammation model of RAW264.7 cells

[0073] RAW 264.7 macrophages were seeded into wells of a plate. When the cells reached 70-80% confluence, they were treated with culture medium, followed by stimulation with 1000 ng / mL lipopolysaccharide (LPS). The control group received only an equal volume of culture medium. After treatment, the cell culture supernatant from each well was carefully collected. The concentration of tumor necrosis factor-α (TNF-α) in the supernatant was determined using an ELISA kit following strict instructions, employing a double-antibody sandwich assay. The expression level of TNF-α in the supernatant of each group was calculated and statistically analyzed.

[0074] 5. Experimental Results

[0075] This invention successfully constructed a high-sugar, high-fat diet model. After the high-sugar, high-fat diet model was established, compared with the control group, the model group mice were significantly larger and their body weight increased significantly (e.g., Figure 1 As shown in the figure, mice can be diagnosed with obesity by calculating their degree of obesity.

[0076] Meanwhile, the model group also showed abnormal blood glucose levels. Further glucose tolerance analysis revealed abnormal glucose metabolism in the model mice, which could be diagnosed as diabetes (e.g., Figure 2 (As shown in Tables 1 and 2).

[0077] Table 1

[0078]

[0079] Table 2

[0080]

[0081] Based on the sperm abnormality rate results, the sperm abnormality rate in the model group mice was significantly increased. Sperm abnormality rate is an important parameter of sperm quality and a key indicator of male fertility. The results indicate that the model group mice experienced reproductive damage (such as...). Figure 3 (As shown in Tables 3 and 4).

[0082] Table 3

[0083]

[0084] Table 4

[0085]

[0086] Combined with biochemical index analysis, it was found that serum uric acid (UA) was significantly elevated in the model group mice. Serum uric acid is commonly seen in gout. Based on the high-sugar, high-fat diet, the model group mice can be diagnosed as having a high risk of gout (e.g., Figure 4 (As shown in Tables A, 5, and 6).

[0087] Furthermore, the results showed that serum low-density lipoprotein (LDL) and the LDL / HDL ratio were significantly elevated in the model group mice. LDL is a direct risk factor for atherosclerotic cardiovascular disease; the LDL / HDL ratio is an important indicator for assessing atherosclerosis. Combined with other indicators, it can be inferred that the model group mice exhibit symptoms of atherosclerosis (such as...). Figure 4 (As shown in B and C, Tables 5 and 6).

[0088] Table 5

[0089]

[0090] Table 6

[0091]

[0092] A comprehensive analysis of combined behavioral results showed that the spontaneous alternation rate, total open field distance, central distance, and central time were all decreased in the model group mice. The spontaneous alternation rate in the Y-maze is a classic indicator for assessing short-term spatial working memory and exploratory motivation in mice; the total open field distance is an important indicator for assessing spontaneous activity behavior in mice; and central distance and central time are the gold standard for evaluating anxiety levels in mice. Combined with other indicators, it can be concluded that the model group mice exhibited impaired cognitive function, reduced activity, and an anxiety-like emotional state (e.g., ...). Figure 5 (As shown in Tables 7 and 8). Intervention with Christensenella minuta and / or its metabolites significantly reduced blood glucose levels, serum uric acid, and serum low-density lipoprotein (LDL), and improved abnormal glucose metabolism and cognitive function, while also improving reproductive damage caused by abnormal glucose and lipid metabolism. The results showed that Christensenella minuta intervention significantly reduced serum LDL and uric acid in high-glucose, high-fat mice compared to the standard, and this effect was dose-dependent.

[0093] Table 7

[0094]

[0095] Table 8

[0096]

[0097] Table 9

[0098]

[0099] Example 2

[0100] Fecal gut microbiota sequencing:

[0101] On the last day of the experiment, fresh feces were collected from mice. Following the instructions of the kit, DNA was extracted from the samples and subjected to qualitative and quantitative analysis. Then, 16S rRNA was subjected to long-read sequencing to analyze the changes in the composition and abundance of gut microbiota in feces, as well as the colonization of Christensenella minuta in the gut.

[0102] Christensenella minuta intervention effectively restored gut microbiota diversity and significantly increased the relative abundance of Christensenella minuta, reflecting that Christensenella minuta can effectively colonize the gut after intervention, regulate gut ecology, and improve symptoms such as abnormal glucose and lipid metabolism.

[0103] Therefore, Christensenella minuta can be applied to fecal microbiota transplantation (FMT) and the regulation of gut microbiota health.

[0104] This invention points out the role of Christensenella minuta in the preparation of products for the prevention, treatment and / or adjunctive treatment of obesity and related symptoms of glucose and lipid metabolism disorders induced by daily high-sugar and high-fat diets. It also finds that Christensenella minuta can serve as an effective functional component for reducing hyperglycemia, reducing the risk of gout, reducing the occurrence of atherosclerosis and improving reproductive damage and cognitive impairment caused by glucose and lipid metabolism disorders.

[0105] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. Christensenella minuta, characterized by, Its accession number is: CGMCCNo.46901.

2. A microbial inoculant, characterized in that, Includes any of the following and acceptable adjuvants: (a) Christensenella minuta as described in claim 1; and / or (b) Inactivated Christensenella minuta as described in claim 1; and / or (c) Metabolites, derivatives, fermentation broths, cultures, exosomes, lysates, or extracts of Christensenella minuta as described in claim 1.

3. The use of Christensenella minuta as described in claim 1 and / or the microbial agent as described in claim 2 in the preparation of products for treating and / or preventing obesity and / or lowering blood sugar.

4. The use of Christensenella minuta as described in claim 1 and / or the microbial agent as described in claim 2 in the preparation of products that improve abnormal glucose metabolism.

5. The use of Christensenella minuta as described in claim 1 and / or the microbial agent as described in claim 2 in the preparation of products that lower low-density lipoprotein.

6. The use of Christensenella minuta as described in claim 1 and / or the microbial agent as described in claim 2 in the preparation of products that improve reproductive damage.

7. The use of Christensenella minuta as described in claim 1 and / or the microbial agent as described in claim 2 in the preparation of products that regulate intestinal microecology.

8. The application as described in claim 7, characterized in that, The Christenella minuta and / or the microbial agent regulate fecal microbiota transplantation.

9. The use of Christensenella minuta as described in claim 1 and / or the microbial agent as described in claim 2 in the preparation of products that improve cognitive function.

10. The use of Christensenella minuta as described in claim 1 and / or the microbial agent as described in claim 2 in the preparation of products that lower uric acid.

Images